Neoadjuvant Treatment Versus Upfront Surgery in Resectable Pancreatic Cancer: A Cost-Effectiveness Analysis.
Simran ArjaniVishnu PrasathNipun SuriSharon LiSushil AhlawatRavi J ChokshiPublished in: JCO oncology practice (2022)
It is more cost-effective to administer NACRT before surgery for patients with resectable PC. On the basis of sensitivity analyses, USR with adjuvant therapy is only favored if rates of resection and eligibility for resection after NACRT decrease. NACRT should be considered in all patients unless there is an absolute contraindication.
Keyphrases
- minimally invasive
- locally advanced
- coronary artery bypass
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- rectal cancer
- peritoneal dialysis
- lymph node
- squamous cell carcinoma
- prognostic factors
- radiation therapy
- patient reported outcomes
- coronary artery disease
- percutaneous coronary intervention
- atrial fibrillation
- patient reported
- replacement therapy
- data analysis